ARVO 2025: Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma

Published on May 9, 2025
The first-in-class endothelin antagonist intravitreal implant aided in increasing ocular blood flow and improved both visual function and anatomic structure, according to the company.
Continue reading on website
Other news

Prevent Blindness voices support for reintroduction of EDVI Act

May 9, 2025
The Early Detection of Vision Impairments for Children Act (EDVI), or HR 2527, would allow the federal government to award grants and cooperative agreements to eligible states and communities for children's vision care initiatives.

Counterpoint: Minnesotans, ophthalmologists are trying to pull the wool over your eyes

May 9, 2025
Proposed legislation maintains standards but would expand access for patients.